Analyst Consensus ?
ConsensusHold42 ratings
Bullish1535.7%
Neutral2559.5%
Bearish24.8%
FN2 Earnings Intelligence
Universal Health Services, Inc. (UHS) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 14, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| RBC Capital | Sector Perform | Sector Perform | Maintain | Aug 20, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jul 30, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 29, 2026 |
| Guggenheim | Buy | Buy | Maintain | Jul 29, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Jul 29, 2026 |
| Baird | Neutral | Neutral | Maintain | Jul 29, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 28, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 13, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jun 22, 2026 |
| UBS | Buy | Buy | Maintain | Apr 30, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Aug 4, 2025 |
| B of A Securities | Underperform | Neutral | Downgrade | Jul 16, 2025 |
| Stephens & Co. | Equal Weight | Equal Weight | Maintain | Feb 28, 2025 |
| Deutsche Bank | Buy | Buy | Maintain | Apr 12, 2024 |
| Mizuho | Buy | Buy | Maintain | Mar 6, 2024 |
| Citigroup | Buy | Buy | Maintain | Feb 29, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Jul 27, 2023 |
| SVB Securities | Outperform | Market Perform | Upgrade | May 26, 2023 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Mar 1, 2023 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Oct 27, 2022 |
| BMO Capital | Underperform | Market Perform | Downgrade | Jul 6, 2022 |
| Loop Capital | Hold | Hold | Maintain | Jun 17, 2022 |
| Seaport Global | Neutral | Buy | Downgrade | Feb 28, 2022 |
| Piper Sandler | Neutral | Neutral | Maintain | Feb 28, 2022 |
| Bank of America | Buy | Neutral | Upgrade | Sep 18, 2018 |
| PiperJaffray | Neutral | Overweight | Downgrade | Jan 3, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | Sep 22, 2017 |
| Raymond James | Market Perform | Outperform | Downgrade | Dec 14, 2016 |
| Avondale Partners | Market Perform | Market Outperform | Downgrade | Nov 9, 2016 |
| Wallachbeth | Hold | Buy | Downgrade | Oct 11, 2016 |
| Sterne Agee CRT | Neutral | Underperform | Upgrade | Mar 2, 2016 |
| Sterne Agee | Neutral | Underperform | Upgrade | Mar 2, 2016 |
| Standpoint Research | Buy | Hold | Upgrade | Feb 10, 2016 |
| KeyBanc | Overweight | Sector Weight | Upgrade | Oct 1, 2015 |
| Janney Capital | Neutral | Neutral | Maintain | Jun 10, 2015 |
| FBR Capital | Outperform | Outperform | Maintain | Apr 28, 2014 |
| Monness Crespi Hardt | Neutral | Neutral | Maintain | Mar 31, 2014 |
| Susquehanna | Neutral | Positive | Downgrade | May 17, 2013 |
| WallachBeth Capital | Hold | Buy | Downgrade | Mar 4, 2013 |
| Imperial Capital | Outperform | Outperform | Maintain | Sep 13, 2012 |
| Jefferies | Hold | Hold | Maintain | Apr 27, 2012 |
| Auriga | Buy | Buy | Maintain | Feb 28, 2012 |
Upside is calculated against the persisted current price $173.25. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| RBC Capital | Ben Hendrix | $183 | $171.8 | +5.6% | Aug 3, 2026 |
| Goldman Sachs | Analyst unavailable | $190 | $168.16 | +9.7% | Jul 30, 2026 |
| UBS | Analyst unavailable | $290 | $166.22 | +67.4% | Jul 29, 2026 |
| Guggenheim | Jason Cassorla | $189 | $166.22 | +9.1% | Jul 29, 2026 |
| Robert W. Baird | Analyst unavailable | $166 | $166.22 | -4.2% | Jul 29, 2026 |
| Morgan Stanley | Craig Hettenbach | $191 | $166.22 | +10.2% | Jul 29, 2026 |
| Barclays | Analyst unavailable | $168 | $159.31 | -3.0% | Jul 28, 2026 |
| Guggenheim | Analyst unavailable | $195 | $151.16 | +12.6% | Jul 20, 2026 |
| Wells Fargo | Analyst unavailable | $166 | $155.57 | -4.2% | Jul 13, 2026 |
| Barclays | Analyst unavailable | $179 | $161.26 | +3.3% | Jul 8, 2026 |
| Wells Fargo | Analyst unavailable | $165 | $146.11 | -4.8% | Jun 1, 2026 |
| UBS | Analyst unavailable | $310 | $167.86 | +78.9% | Apr 30, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $194 | $167.51 | +12.0% | Apr 29, 2026 |
| RBC Capital | Analyst unavailable | $190 | $162.54 | +9.7% | Apr 29, 2026 |
| Guggenheim | Analyst unavailable | $211 | $162.54 | +21.8% | Apr 29, 2026 |
| Robert W. Baird | Michael Ha | $204 | $162.54 | +17.7% | Apr 29, 2026 |
| Barclays | Analyst unavailable | $238 | $179.51 | +37.4% | Apr 28, 2026 |
| Barclays | Analyst unavailable | $262 | $203.68 | +51.2% | Jan 22, 2026 |
| UBS | Analyst unavailable | $245 | $214.97 | +41.4% | Jan 7, 2026 |
| Wells Fargo | Analyst unavailable | $235 | $221.74 | +35.6% | Jan 7, 2026 |
| Guggenheim | Jason Cassorla | $274 | $239.43 | +58.2% | Dec 2, 2025 |
| Raymond James | John Ransom | $270 | $217.01 | +55.8% | Nov 3, 2025 |
| UBS | Analyst unavailable | $231 | $225.3 | +33.3% | Oct 30, 2025 |
| RBC Capital | Ben Hendrix | $231 | $223.61 | +33.3% | Oct 30, 2025 |
| UBS | Analyst unavailable | $302 | $219.32 | +74.3% | Oct 29, 2025 |
| Guggenheim | Jason Cassorla | $253 | $219.32 | +46.0% | Oct 29, 2025 |
| Morgan Stanley | Craig Hettenbach | $233 | $219.32 | +34.5% | Oct 29, 2025 |
| Barclays | Analyst unavailable | $263 | $214.03 | +51.8% | Oct 28, 2025 |
| Mizuho Securities | Ann Hynes | $242 | $214.03 | +39.7% | Oct 28, 2025 |
| Goldman Sachs | Analyst unavailable | $219 | $197.76 | +26.4% | Oct 14, 2025 |
| Wells Fargo | Analyst unavailable | $249 | $209.11 | +43.7% | Oct 7, 2025 |
| Robert W. Baird | Michael Ha | $203 | $177.91 | +17.2% | Aug 14, 2025 |
| UBS | Analyst unavailable | $227 | $165.44 | +31.0% | Jul 30, 2025 |
| Morgan Stanley | Analyst unavailable | $200 | $184.46 | +15.4% | Mar 26, 2025 |
| Robert W. Baird | Michael Ha | $274 | $236.47 | +58.2% | Sep 4, 2024 |
| Raymond James | Sarah James | $219 | $204.99 | +26.4% | Jul 26, 2024 |
| Barclays | Andrew Mok | $256 | $210.68 | +47.8% | Jul 26, 2024 |
| Robert W. Baird | Michael Ha | $236 | $187.7 | +36.2% | Jun 26, 2024 |
| HSBC | Sidharth Sahoo | $290 | $94 | +67.4% | Jun 5, 2024 |
| UBS | AJ Rice | $226 | $177.7 | +30.4% | May 20, 2024 |
| RBC Capital | Frank Morgan | $189 | $169.15 | +9.1% | May 7, 2024 |
| Deutsche Bank | Pito Chickering | $203 | $168.4 | +17.2% | Apr 12, 2024 |
| Stephens | Scott Fidel | $185 | $182.46 | +6.8% | Apr 1, 2024 |
| Barclays | Steven Valiquette | $142 | $140.7 | -18.0% | Apr 25, 2023 |
| Barclays | Analyst unavailable | $132 | $152.21 | -23.8% | Jan 9, 2023 |
| Wells Fargo | Stephen Baxter | $154 | $142.04 | -11.1% | Jan 3, 2023 |
| Goldman Sachs | Analyst unavailable | $110 | $102.03 | -36.5% | Jul 12, 2022 |
| Credit Suisse | Analyst unavailable | $141 | $102.24 | -18.6% | Jul 1, 2022 |
| Mizuho Securities | Analyst unavailable | $121 | $102.07 | -30.2% | Jul 1, 2022 |
| Mizuho Securities | Analyst unavailable | $153 | $124.98 | -11.7% | May 3, 2022 |
| Wells Fargo | Analyst unavailable | $118 | $124.16 | -31.9% | Apr 28, 2022 |
| Stephens | Analyst unavailable | $135 | $124.32 | -22.1% | Apr 27, 2022 |
| Credit Suisse | Analyst unavailable | $158 | $125.32 | -8.8% | Apr 27, 2022 |
| RBC Capital | Analyst unavailable | $130 | $125.32 | -25.0% | Apr 27, 2022 |
| Mizuho Securities | Ann Hynes | $145 | $69.38 | -16.3% | Apr 26, 2022 |
| Goldman Sachs | Jamie Perse | $135 | $128.04 | -22.1% | Nov 9, 2021 |
| Stephens | Scott Fidel | $142 | $124.54 | -18.0% | Oct 27, 2021 |
| BMO Capital | Matthew Borsch | $145 | $124.54 | -16.3% | Oct 27, 2021 |
| Bank of America Securities | Kevin Fischbeck | $153 | $125.79 | -11.7% | Oct 26, 2021 |
| Credit Suisse | A.J. Rice | $181 | $158.43 | +4.5% | Jul 27, 2021 |
| Wolfe Research | Justin Lake | $171 | $151.2 | -1.3% | Jun 21, 2021 |
Track every rating change on UHS the moment it posts. Free to start.
Start free